Your browser doesn't support javascript.
loading
Higher Myonuclei Density in Muscle Fibers Persists Among Former Users of Anabolic Androgenic Steroids.
Nielsen, Jakob Lindberg; Rasmussen, Jon Jarløv; Frandsen, Mikkel Nicklas; Fredberg, Jeppe; Brandt-Jacobsen, Niels Høegh; Aagaard, Per; Kistorp, Caroline.
Afiliação
  • Nielsen JL; Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense DK-5230, Denmark.
  • Rasmussen JJ; Department of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen DK-2200, Denmark.
  • Frandsen MN; Department of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen DK-2200, Denmark.
  • Fredberg J; Department of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen DK-2200, Denmark.
  • Brandt-Jacobsen NH; Department of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen DK-2200, Denmark.
  • Aagaard P; Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense DK-5230, Denmark.
  • Kistorp C; Department of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen DK-2200, Denmark.
J Clin Endocrinol Metab ; 109(1): e266-e273, 2023 Dec 21.
Article em En | MEDLINE | ID: mdl-37466198
ABSTRACT
CONTEXT No information exists on the long-lasting effects of supraphysiological anabolic androgenic steroids (AASs) usage on the myocellular properties of human skeletal muscle in previous AAS users.

OBJECTIVE:

We hypothesized that former AAS users would demonstrate smaller myonuclei domains (ie, higher myonuclei density) than matched controls.

METHODS:

A community-based cross-sectional study in men aged 18-50 years engaged in recreational strength training. Muscle biopsies were obtained from the m. vastus lateralis. Immunofluorescence analyses were performed to quantify myonuclei density and myofiber size.

RESULTS:

Twenty-five males were included 8 current and 7 previous AAS users and 10 controls. Median (25th-75th percentiles) accumulated duration of AAS use was 174 (101-206) and 140 (24-260) weeks in current and former AAS users, respectively (P = .482). Geometric mean (95% CI) elapsed duration since AAS cessation was 4.0 (1.2; 12.7) years among former AAS users. Type II muscle fibers in former AAS users displayed higher myonuclei density and DNA to cytoplasm ratio than controls, corresponding to smaller myonuclei domains (P = .013). Longer accumulated AAS use (weeks, log2) was associated with smaller myonuclei domains in previous AAS users beta-coefficient (95% CI) -94 (-169; -18), P = .024. Type I fibers in current AAS users exhibited a higher amount of satellite cells per myofiber (P = .031) than controls.

CONCLUSION:

Muscle fibers in former AAS users demonstrated persistently higher myonuclei density and DNA to cytoplasm ratio 4 years after AAS cessation suggestive of enhanced retraining capacity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esteróides Androgênicos Anabolizantes / Anabolizantes Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esteróides Androgênicos Anabolizantes / Anabolizantes Idioma: En Ano de publicação: 2023 Tipo de documento: Article